Revaccination doses of hepatitis B vaccine for young adults
The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
This study tests the best way to give the hepatitis B vaccine to young adults in Taiwan who are at high risk and don't have enough protection against the virus.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 240 (estimated) |
| Ages | 20 Years to 36 Years |
| Sex | All |
| Sponsor | National Taiwan University Hospital Academic / other |
| Locations | 1 site (Taipei) |
| Trial ID | NCT04970836 on ClinicalTrials.gov |
What this trial studies
This prospective cohort study investigates the optimal revaccination doses of the hepatitis B vaccine for high-risk young adults in Taiwan who lack protective antibodies. Participants aged 20-33, born after 1987, will be grouped based on their antibody levels and receive one or two doses of the vaccine. The study aims to determine the most effective dosing strategy to enhance protection against hepatitis B infection. Participants will be monitored for 12 months to assess their antibody response.
Who should consider this trial
Good fit: Ideal candidates are young adults aged 20-33, born in Taiwan after 1987, who have received a full course of hepatitis B vaccination but currently lack protective antibodies.
Not a fit: Patients who have previously been vaccinated against hepatitis B or those with a positive test for hepatitis B antibodies or antigens will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a tailored vaccination strategy that enhances protection against hepatitis B for high-risk young adults.
How similar studies have performed: While similar studies on hepatitis B vaccination have been conducted, this specific approach to revaccination in this age group is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The actual age at the time of admission was higher than 20 years old and birth year after 1987 2. Born in Taiwan and had received a full course of hepatitis B vaccines at least three doses at infant period. 3. Those who have tested negative for hepatitis B surface antibody and surface antigen at baseline 4. Have never been vaccinated against hepatitis B in childhood and adolescence by questionnaire 5. Consent to administer 1-2 doses of hepatitis B vaccine according to the assigned group after sharing decision making process 6. In good health Exclusion Criteria: 1. Those who were previously allergic to hepatitis B vaccine or its components (such as yeast) 2. Those who have been vaccinated against hepatitis B during childhood and adolescence 3. Those who have a positive test for hepatitis B surface antibody or a positive test for hepatitis B surface antigen
Where this trial is running
Taipei
- Family Medicine, NTUH — Taipei, Taiwan (Recruiting)
Study contacts
- Principal investigator: CHYI-FENG JAN, MD, PhD — National Taiwan University Hospital
- Study coordinator: Chyi-Feng Jan, Md, Phd
- Email: jcf036@gmail.com
- Phone: +886-2-23123456
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.